EcoDrugPlus

Rela Proto-Oncogene, Nf-Kb Subunit

Ensembl ID : ENSDLEG00000003353
Gene Symbol: RELA
3 Cross references
200 Possible Orthologues:

Ros Proto-Oncogene 1, Receptor Tyrosine Kinase

Ensembl ID : ENSDLEG00000009633
Gene Symbol: ROS1
1 Cross references
125 Possible Orthologues:

Raf-1 Proto-Oncogene, Serine/threonine Kinase

Ensembl ID : ENSDLEG00000007956
Gene Symbol: RAF1
3 Cross references
224 Possible Orthologues:

Rho Associated Coiled-Coil Containing Protein Kinase 1

Ensembl ID : ENSDLEG00000001559
Gene Symbol: ROCK1
1 Cross references
211 Possible Orthologues:

Sem1 26s Proteasome Complex Subunit

Ensembl ID : ENSDLEG00000018983
Gene Symbol: SEM1
3 Cross references
156 Possible Orthologues:

Src Proto-Oncogene, Non-Receptor Tyrosine Kinase

Ensembl ID : ENSDLEG00000013281
Gene Symbol: SRC
3 Cross references
261 Possible Orthologues:

Tek Receptor Tyrosine Kinase

Ensembl ID : ENSDLEG00000020783
Gene Symbol: TEK
3 Cross references
166 Possible Orthologues:

Ttk Protein Kinase

Ensembl ID : ENSDLEG00000001116
Gene Symbol: TTK
1 Cross references
205 Possible Orthologues:

Udp-Glucose Ceramide Glucosyltransferase

Ensembl ID : ENSDLEG00000004789
Gene Symbol: UGCG
3 Cross references
212 Possible Orthologues:

Yes Proto-Oncogene 1, Src Family Tyrosine Kinase

Ensembl ID : ENSDLEG00000001143
Gene Symbol: YES1
3 Cross references
260 Possible Orthologues:

Acetylcholinesterase (Cartwright Blood Group)

Ensembl ID : ENSDLEG00000008179
Gene Symbol: ACHE
3 Cross references
234 Possible Orthologues:

Activin A Receptor Like Type 1

Ensembl ID : ENSDLEG00000004485
Gene Symbol: ACVRL1
3 Cross references
358 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).